Expert opinion on rotavirus vaccination in infancy
ECDC has published an Expert Opinion on rotavirus vaccination in infancy. The paper provides EU/EEA Member States with relevant scientific information on burden of rotavirus disease, vaccine effectiveness and safety, and cost-effectiveness studies to support the decision-making process on the possible introduction of routine vaccination of children against rotavirus gastroenteritis.
Expert opinion on rotavirus vaccination in infancy: public consultation opens
The final expert opinion on rotavirus vaccination in infancy aims to provide EU/EEA Member States with information to support the decision-making process on the possible introduction of rotavirus vaccination in infancy.
Effectiveness of rotavirus vaccination: Generic study protocols for retrospective case control and cohort studies based on computerised databases
In Europe, routine rotavirus vaccination of infants at the national level has been introduced with one or two vaccine brands in Finland, Austria, Luxembourg and Belgium within well-baby clinics or administered by general practitioners and paediatricians. When introducing a new vaccine, it is crucial to conduct studies evaluating the vaccination’s impact and effectiveness in order to decide on recommendations for its future use.
ECDC Vaccine Scheduler
The Vaccine Scheduler is an interactive tool that shows vaccination schedules for individual EU/EEA countries and specific age groups. With this tool comparisons can be made for vaccination schedules between two countries or by disease for all or a selection of countries.
- hepatitis A
- hepatitis B
- human papillomavirus infection
- influenza in humans, seasonal
- invasive Haemophilus influenzae disease
- meningococcal disease
- pneumococcal disease
- prevention and control
- rotavirus infection
- tick-borne diseases
Safety, Reactogenicity and Immunogenicity of the Human Rotavirus Vaccine in Pre-Term European Infants: A Randomized Phase IIIb StudyArchived
Results of this study demonstrated that the RIX4414 vaccine was well tolerated and immunogenic in pre-term European infants: more than 75% of infants had seroconverted 30-83 days after dose 2.
Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in IrelandArchived
Rotavirus gastroenteritis in Ireland is a quite common and unpleasant illness, but severe disease is unusual and death extremely rare. Nonetheless, rotavirus generates considerable direct and indirect costs.
Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trialArchived
These article published in The Lancet provide new data for the efficacy of oral pentavalent rotavirus vaccine for prevention of severe rotavirus – related gastroenteritis in infant in developing countries
Herd immunity after two years of the universal mass vaccination program against rotavirus gastroenteritis in AustriaArchived
This paper describes the epidemiology of rotavirus (RV) in Austrian children before and during universal mass campaign.